Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 8477 publications.

Brogan A. Advancing accuracy and transparency in health economic evaluation. Presentation to be given at the ISPOR 2025; May 16, 2025. Montreal, Canada.

Bozzi LM, Johnson R, Heidenreich S, Poulos C. Alternative recruitment options for patient preference studies: thinking outside the market research panel box. Presentation to be given at the ISPOR 2025; May 16, 2025. Montréal, Canada.

Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster to be given at the ISPOR 2025; May 16, 2025. Montréal, Canada.

Copley-Merriman K, Doward L, Hawe E, Cope S. Clinical trial design, beyond the regulatory. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Riemer J, Campbell K, Arthurs E, Knight C. Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Loria-Rebolledo L, Watson V, Mohan D, Vass CM, Antunes M, Burns D, Ryan M. Over 30 years of discrete choice experiment studies in health economics: systematic review of current practice and reflections on evolving practice. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Herring WL, Coon C, Lenderking W, Whittington M. Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Marcano Belisario J, Lunan M, Hawe E, Farrelly G. Evaluation of machine learning assisted title and abstract screening in 5 clinical systematic literature reviews. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N. Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Presentation to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Buck PM, Masaquel C. The most heavily managed drug categories on Part D formularies. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Sauchelli S, Chicklis EK, Carty MK, Gnanasakthy A. Use of diaries to capture patient-reported outcomes in FDA new drug approvals (2019-2023). Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Pizzi L, Earnshaw S, Blanchette C, Thompson D. Climbing the HEOR career ladder: strategies for success in an era of change. Presentation to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Dellon ES, Goodwin B, Liu E, de los Santos B, Korgaonkar S, Meyers J, Schaeffer-Koziol CR, Terreri B, Shah ED. Eosinophilic esophagitis-related healthcare resource utilization and associated costs for payers and patients: a retrospective cohort study of US health insurance claims data. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Presentation to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Ronquest N, Zhang Y, Mladsi D. Assessing the impact of the United States (US) inflation reduction act (IRA) regulations on investment incentives for orphan disease drug development. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The potential public health and economic benefit of an mRNA-based RSV vaccine, mRNA-1345, among high-risk adults aged 18-59 years in the US: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Gnanasakthy A, Crawford R, Qin S, Doward L, Rockwood NJ. Advanced patient-reported outcomes. Presentation to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada. Previously presented at the ISPOR Europe 2024.

Garcia de Albeniz Martinez X. Validate study variables to reduce misclassification bias: recent tools and research needs. Presentation to be given at the ARS Toscana Webinar; March 27, 2025. Florence, Italy.

Paret K, Chaiyakunapruk N, Ronquest N, Pearson I. Introduction to best practices for country adaptations of economic models - virtual. Presentation to be given at the 2025 Virtual ISPOR Short Course Program; March 26, 2025. Previously presented at the 2024 Virtual ISPOR Short Course Program.

Vila Guilera J, Abellan A, Garcia de Albeniz X, Houghton K. External control arm studies in marketing authorisation applications submitted to the European Medicines Agency: a review of study design features and methods. Presented at the Drug Information Association (DIA) Europe 2025; March 18, 2025. Basel, Switzerland.

Rodriguez-Buritica DF, Dine J, Brown TM, Romano (DeMuro) C, Bratlee-Whitaker E, Ferrecchia I, Temkin G, Mora JJ, Babakhani RA, Ko JJ, Weinstein D. Qualitative interviews to support the development of a Patient-Reported Outcome (PRO) measure for glycogen storage disease type Ia. Poster presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting; March 18, 2025. Los Angeles, CA.

La EM, Sweeney C, Davenport E, Calhoun S, Harmelink A, Singer D. Healthcare professionals' knowledge, attitudes, and practices regarding respiratory syncytial virus disease and vaccination in adults aged 60 years and older. Infect Dis Ther. 2025 Mar 14. doi: 10.1007/s40121-025-01119-0

Megias-Vericat JE, Escolar G, Wilson MR, Mendez P, McDade CL, Barrientos LV, Tomic R, Panebianco M, Linden S, Yan S. Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain. J Med Econ. 2025 Mar 7;1-13. doi: 10.1080/13696998.2025.2474886

Hill NL, Bhargava S, Do J, Bratlee-Whitaker EM, Brown MJ, Komalasari R, Wu R, Mogle J. Just as expected? Older adults' aging expectations are associated with subjective cognition. Aging Ment Health. 2025 Mar 1;29(3):444-51. doi: 10.1080/13607863.2024.2399080

Greenhawt M, Bansal P, Goodwin B, Korgaonkar S, Liu Y, Meyers J, Shah E, Terreri B, Dellon E, Schaeffer-Koziol C. High incidence and prevalence of eosinophilic esophagitis in the USA identified: an analysis of US health insurance claims data. Poster presented at the 2025 American Academy of Allergy Asthma & Immunology (AAAAI)/WAO Joint Congress; February 28, 2025. San Diego, CA.

Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Plain language summary of mortality rates of patients with Parkinson's disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics. Futur Neurol. 2025 Feb 28;20(1). doi: 10.1080/14796708.2025.2463315

Kovesdy CP, Ebert N, Vizcaya D, Walsh M, Kosiborod MN, Layton JB, Ziemiecki R, Johannes CB, Pladevall-Vila M, Gee PO, Jefferson N, Chicoye A, Lopes M, Thapa BB, Curhan G, Rangel L, Bhartia M, Liu F, Farjat AE, Oberprieler NG. Change in urine albumin-creatinine ratio and occurrence of hyperkalemia in patients initiating finerenone in the United States: a cohort study from the FOUNTAIN platform. Nephron. 2025 Feb 27;1-26. doi: 10.1159/000543923

Murillo ER, Mora JRM, Bachiller MM, Santiago LG, Braque NN, Bravo MO. Factors associated with low adherence to inhaled therapy in patients with chronic respiratory diseases: a cross-sectional study. BMC Pulm Med. 2025 Feb 27;25(1):94. doi: 10.1186/s12890-025-03563-7.

Khanji C, Nuabor W, Gould T, Kim HK, Barrows S, Herbel B, Njue A. Systematic literature review of outcomes associated with adherence to haemophilia drug therapy. Haemophilia. 2025 Feb 25. doi: 10.1111/hae.15153

Pritchard C, Kutikova L, Pitman R, Lai KZH, Beyhaghi H, Gibbons I, Erbe A, Zivkovic-Gojovic M, Cosgrove C, Sculpher M, Salisbury D. Cost-effectiveness of introducing nuvaxovid to COVID-19 vaccination in the United Kingdom: a dynamic transmission model. Vaccines (Basel). 2025 Feb 14;13(2):187. doi: 10.3390/vaccines13020187

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Feb 13;1-10. doi: 10.1080/14796694.2025.2464485

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Feb 12. doi: 10.1080/14796694.2025.2463276

Viguerie A, O'Shea J, Johnston M, Schreiber D, Adams J, Bates L, Carrico J, Hicks KA, Lyles CM, Farnham PG. Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines. AIDS. 2025 Feb 5. doi: 10.1097/QAD.0000000000004144

Law EH, Hanson KA, Harries M, Korver D, Sherif B, Chirila C. Patient-reported outcome improvements following scalp hair regrowth among patients with alopecia areata: analysis of the ALLEGRO-2b/3 trial. J Dermatolog Trea. 2025 Feb 3;36(1):2460577. doi: 10.1080/09546634.2025.2460577

Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Chen ST, Katzka DA. Satisfaction with and adherence to off-label corticosteroids in adolescents and adults with eosinophilic esophagitis: results of a web-based survey in the United States. J Clin Gastroenterol. 2025 Feb;59(2):138-46. doi: 10.1097/MCG.0000000000002006

Abellan A, Burn E, Trinh NTH, Burkard T, Callahan A, Fernandez-Bertolin S, Hurley E, Rodriguez C, Segundo E, Morales DR, M E Nordeng H, Duarte-Salles T. Expanding the OMOP common data model to support perinatal research in network studies. Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70106. doi: 10.1002/pds.70106

Poulos C, Marcek T, Chintakayala P, Boeri M, Francis A, Langevin E, Petigara T, O'Connor J, Samant S. Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan 29. doi: 10.1080/14737167.2025.2450352

Vickers AD. A comparison of the performance of six surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis. Value Health. 2025 Jan 27. doi: 10.1016/j.jval.2025.01.005

Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18. doi: 10.1177/17562864241310996

Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Jan 26;1-13. doi: 10.1080/14796694.2025.2454895

Tripathee S, Treweek S, Van Hemelrijck M, Ross P, Watson V, MacLennan G, Guntupalli AM, Adams J, Majmudar B, Murchie P, Bekheit M, MacLennan SJ, ICANEQUAL Community of Expertise. ICANEQUAL multi-stakeholder partnership: reducing inequalities in liver cancer (HCC) diagnosis, treatment and care across the UK. NIHR open research. 2025 Jan 21;5:5. doi: 10.3310/nihropenres.13723.1

Craig T, Baptist AP, Anderson J, Zaragoza-Urdaz RH, Burnette AF, Kelbel TE, Riedl MA, Vanegas A, Boyle K, Bartsch JL, Darden C, Brown TM, Schultz BG, Blair C, Sing K, Fox D, Juethner S. Hereditary angioedema: patient health care experiences within underrepresented racial and ethnic groups in the United States. Ann Allergy Asthma Immunol. 2025 Jan 20. doi: 10.1016/j.anai.2025.01.007

Dine J, Guan Y, Milien M, Ervin C, Byrne DD, Brown ML, De Anda C, Norquist JM. Evaluation of the content validity of the COVID-19 symptoms daily diary. Patient Relat Outcome Meas. 2025 Jan 17;16:37-53. doi: 10.2147/PROM.S488914

Wright GC, Zueger PM, Copley-Merriman K, Khan S, Costello J, Krumbach A, Reddy P, Tanjinatus O, Wells AF. Health disparities in rheumatology in the United States. Open Access Rheumatol. 2025 Jan 9;17:1-12. doi: 10.2147/OARRR.S493457